Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial

被引:40
作者
Atencio, IA
Grace, M
Bordens, R
Fritz, M
Horowitz, JA
Hutchins, B
Indelicato, S
Jacobs, S
Kolz, K
Maneval, D
Musco, ML
Shinoda, J
Venook, A
Wen, S
Warren, R
机构
[1] Canji Inc, San Diego, CA 92121 USA
[2] Schering Plough Res Inst, Kenilworth, NJ USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
adenovirus; p53; clinical trial; intrahepatic arterial administration; cancer; gene therapy;
D O I
10.1038/sj.cgt.7700870
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The major focus of intrahepatic arterial (IHA) administration of adenoviruses (Ad) has been on safety. Currently, there is little published data on the biological responses to Ad when administered via this route. As part of a Phase I study, we evaluated biological responses to a replication-defective adenovirus encoding the p53 transgene (SCH 58500) when administered by hepatic arterial infusion to patients with primarily colorectal cancer metastatic to the liver. In analyzing biological responses to the Ad vector, we found that both total and neutralizing Ad antibodies increased weeks after SCH 58500 infusion. The fold increase in antibody titers was not dependent on SCH 58500 dosage. The proinflammatory cytokine interleukin-6 (IL-6) transiently peaked within 6 h of dosing. The cytokine sTNF-R2 showed elevation by 24 h post-treatment, and fold increases were directly related to SCH 58500 doses. Cytokines TNF-alpha, IL-1 beta, and sTNF-R1 showed no increased levels over 24 h. Predose antibody levels did not appear to predict transduction, nor did serum Ad neutralizing factor (SNF). Delivery of SCH 58500 to tumor tissue occurred, though we found distribution more predominantly in liver tissues, as opposed to tumors. RT-PCR showed significantly higher expression levels (P < 0.0001, ANOVA) for adenovirus type 2 and 5 receptor (CAR) in liver tissues, suggesting a correlation with transduction. Evidence of tumor-specific apoptotic activity was provided by laser scanning cytometry, which determined a coincidence of elevated nuclear p53 protein expression with apoptosis in patient tissue. IHA administration of a replication defective adenovirus is a feasible mode of delivery, allowing for exogenous transfer of the p53 gene into target tissues, with evidence of functional p53. Limited and transient inflammatory responses to the drug occurred, but pre-existing immunity to Ad did not preclude SCH 58500 delivery.
引用
收藏
页码:169 / 181
页数:13
相关论文
共 41 条
  • [1] Anderson SC, 1998, CLIN CANCER RES, V4, P1649
  • [2] Bookstein R, 1996, SEMIN ONCOL, V23, P66
  • [3] A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
    Buller, RE
    Runnebaum, IB
    Karlan, BY
    Horowitz, JA
    Shahin, M
    Buekers, T
    Petrauskas, S
    Kreienberg, R
    Slamon, D
    Pegram, M
    [J]. CANCER GENE THERAPY, 2002, 9 (07) : 553 - 566
  • [4] Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500
    Buller, RE
    Shahin, MS
    Horowitz, JA
    Runnebaum, IB
    Mahavni, V
    Petrauskas, S
    Kreienberg, R
    Karlan, B
    Slamon, D
    Pegram, M
    [J]. CANCER GENE THERAPY, 2002, 9 (07) : 567 - 572
  • [5] p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells
    Chen, XB
    Ko, LJ
    Jayaraman, L
    Prives, C
    [J]. GENES & DEVELOPMENT, 1996, 10 (19) : 2438 - 2451
  • [6] Phase I study of direct administration of a replication deficient adenovirus vector containing the E-coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine
    Crystal, RG
    Hirschowitz, E
    Lieberman, M
    Daly, J
    Kazam, E
    Henschke, C
    Yankelevitz, D
    Kemeny, N
    Silverstein, R
    Ohwada, A
    Russi, T
    Mastrangeli, A
    Sanders, A
    Cooke, J
    Harvey, BG
    [J]. HUMAN GENE THERAPY, 1997, 8 (08) : 985 - 1001
  • [7] CYTOKINE, COMPLEMENT, AND ENDOTOXIN PROFILES ASSOCIATED WITH THE DEVELOPMENT OF THE ADULT-RESPIRATORY-DISTRESS-SYNDROME AFTER SEVERE INJURY
    DONNELLY, TJ
    MEADE, P
    JAGELS, M
    CRYER, HG
    LAW, MM
    HUGLI, TE
    SHOEMAKER, WC
    ABRAHAM, E
    [J]. CRITICAL CARE MEDICINE, 1994, 22 (05) : 768 - 776
  • [8] Control of apoptosis by p53
    Fridman, JS
    Lowe, SW
    [J]. ONCOGENE, 2003, 22 (56) : 9030 - 9040
  • [9] Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer
    Fuchs, CS
    Moore, MR
    Harker, G
    Villa, L
    Rinaldi, D
    Hecht, JR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 807 - 814
  • [10] A novel method for real time quantitative RT PCR
    Gibson, UEM
    Heid, CA
    Williams, PM
    [J]. GENOME RESEARCH, 1996, 6 (10): : 995 - 1001